Page 11 - Cipla

Cipla stock rises on strong launch pipeline, FDA approval for injection

Margin gains and steady growth in the Indian market to support the stock, say analysts.

Cipla gains 3% on USFDA's final approval for Lanreotide injection

ICICI Securities remains positive on Cipla's calibrated approach of focusing more on branded products and core therapies across the world

Stocks to Watch: Airtel, ICICI, Hindalco, Shriram Properties, ONGC, Cipla

Consumer Durable stocks are also likely to be in focus on Monday after the company have hiked prices for the third time this year

Cipla receives USFDA nod to market Lanreotide injection in US market

Drug major Cipla on Sunday said it has received approval from the US health regulator to market the Lanreotide injection, used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors, in the American market.

Sensex snaps 4-day losing streak, gains 113pts; Infy, RIL shine; banks slip

The broader markets however finished in red, the breadth too was negative

Drug major Cipla to acquire 33% stake in Clean Max Auriga Power

Post-acquisition, Clean Max Auriga Power LLP will become an associate of Cipla

Glenmark, Alembic, Cipla: Pharma stocks on a booster dose this December

Select pharma stocks look good on the technical charts and may jump up to 15 per cent in December. On the fundamental side, fears of Omicron variant spreading may also keep them in news and buzzing

Pharma stocks rally on buzz about new Covid variant, travel stocks sink

Huge gains for Cipla, Alkem Labs and Dr Lal Path, even as IndiGo, Chalet Hotels and IHC tank

BSE Healthcare index up 2%; Cipla, Alkem, Dr.Reddy's rally up to 8%

The pharma index had taken a breather over the past three months after displaying relative out-performance during CY20-21.

Financials, Reliance drag Sensex down 396 pts; Maruti zooms 7%, M&M 3%

Stock market LIVE: The NSE Nifty swung in a range of 174 points, and finally settled at 17,999, down 110 points

Cipla unit gets notice from US firm for termination of acquisition deal

In November 2018, Cipla had announced that InvaGen Pharmaceuticals Inc has entered into definitive agreements to acquire US-based speciality business firm Avenue Therapeutics

Power crisis brewing in China likely to hit Indian pharma companies

Delays in consignments, rising prices of key ingredients worry industry

Sensex slips 207pts on late sell-off; Axis Bank sheds 6%, Bajaj Finance 5%

Stock market LIVE: Broader indices also trimmed gains at close; PSU banking shares were in demand, while private banking shares witnessed selling pressure

Stocks to Watch: Bajaj Auto, Axis Bank, ITC, Maruti, L&T, SBI Life, Cipla

The broader markets may swing to the global cues, while individual stocks are likely to react to corporate earnings and company specific developments in trade today

Cipla posts 7% year-on-year rise in Q2 PAT, riding on 10% revenue growth

Sequentially, however, the company has posted muted growth-revenue growth of 0.3%, and a PAT decline of 0.5%. Ebitda dipped sequentially too, by 9%

Cipla to sell Eli Lilly's insulin products Humalog, Trulicity in India

Only 3 firms - Novo Nordisk, Sanofi, and Eli Lilly - supply insulin to patients in the US. These three companies, commonly called the 'Big Three', control over 90 per cent of the global insulin market

Cipla eyes acquisitions in India, US after Covid-led windfall

With a funding frenzy currently underway in India, Cipla may struggle to find attractive targets

Hold Nifty long with a stop at Tuesday's low, recommends Vinay Rajani

On the upside, the Nifty may face resistance in the range of 17,950-18,000, says the technical analyst from HDFC Securities

India growth, steady margins are key to near-term upsides for Cipla

Over the medium term, success of the new launches in the US would drive gains

Stocks to watch: M&M, Glenmark Life Sciences, Cipla, Adani Power, Tata Chem

Stocks from the banking, real estate and auto sectors will be in focus amid the RBI policy outcome later today